(AOF) – Biosynex, leader in the Rapid Diagnostic Tests market in France, announces the extension of its partnership with the Singaporean company Credo Diagnostics Biomedical Pte Ltd concerning VitaPCR, Credo Diagnostics’ molecular biology platform capable of detecting infectious pathogens (including SARS-CoV-2 responsible for Covid-19) by the polymerase chain reaction (PCR) method in just 20 minutes.
At the start of the Covid-19 health crisis in March 2020, the two companies had agreed on a distribution agreement for VitaPCR systems for France, Belgium, Switzerland and Luxembourg. The partnership has been extended to the UK.
Thanks to its ease of use, VitaPCR significantly contributes to the decentralization of testing from centralized laboratories to private medical laboratories, general hospitals or even directly to nurses in clinical departments.
Since the launch of this partnership, BIosynex has successfully implemented the VitaPCR solution in more than 300 sites in France, including laboratories, private clinics, hospitals and outsourced sites (airports, cruise ships, companies).
Credo Diagnostics will also launch a next-generation rapid PCR platform, VitaSIRO solo, based on microfluidics that simplifies the entire procedure. The multiplexing capability of the new platform enables the simultaneous detection of influenza, SARS-CoV-2 and the respiratory syncytial virus (RSV) responsible for bronchiolitis.
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.